During the last session, Adc Therapeutics SA (NYSE:ADCT)’s traded shares were 0.64 million, with the beta value of the company hitting 1.55. At the end of the trading day, the stock’s price was $2.02, reflecting an intraday gain of 1.00% or $0.02. The 52-week high for the ADCT share is $6.04, that puts it down -199.01 from that peak though still a striking 28.22% gain since the share price plummeted to a 52-week low of $1.45. The company’s market capitalization is $195.31M, and the average intraday trading volume over the past 10 days was 0.88 million shares, and the average trade volume was 849.29K shares over the past three months.
Adc Therapeutics SA (ADCT) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.29. ADCT has a Sell rating from 0 analyst(s) out of 7 analysts who have looked at this stock. 3 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 4 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be 0.
Adc Therapeutics SA (NYSE:ADCT) trade information
Adc Therapeutics SA (ADCT) registered a 1.00% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 1.00% in intraday trading to $2.02, hitting a weekly high. The stock’s 5-day price performance is -4.72%, and it has moved by -2.42% in 30 days. Based on these gigs, the overall price performance for the year is 21.69%. The short interest in Adc Therapeutics SA (NYSE:ADCT) is 4.12 million shares and it means that shorts have 2.97 day(s) to cover.
The consensus price target of analysts on Wall Street is $8, which implies an increase of 74.75% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $7 and $13 respectively. As a result, ADCT is trading at a discount of -543.56% off the target high and -246.53% off the low.
Adc Therapeutics SA (ADCT) estimates and forecasts
Statistics show that Adc Therapeutics SA has outperformed its competitors in share price, compared to the industry in which it operates. Adc Therapeutics SA (ADCT) shares have gone down -38.04% during the last six months, with a year-to-date growth rate more than the industry average at 42.52% against 16.80. In the rating firms’ projections, revenue will increase 4.55% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 18.85M as predicted by 7 analyst(s). Meanwhile, a consensus of 2 analyst(s) estimates revenue growth to 19.6M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 16.79M and 18.05M respectively. In this case, analysts expect current quarter sales to grow by 12.27% and then jump by 8.57% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -10.46%. While earnings are projected to return 41.93% in 2025.
ADCT Dividends
Adc Therapeutics SA is due to release its next quarterly earnings in February. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Adc Therapeutics SA (NYSE:ADCT)’s Major holders
Adc Therapeutics SA insiders own 20.64% of total outstanding shares while institutional holders control 61.60%, with the float percentage being 77.62%. REDMILE GROUP, LLC is the largest shareholder of the company, while 104.0 institutions own stock in it. As of 2024-06-30, the company held over 15.27 million shares (or 18.4964% of all shares), a total value of $48.25 million in shares.
The next largest institutional holding, with 9.57 million shares, is of PROSIGHT MANAGEMENT, LP’s that is approximately 11.5926% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $30.24 million.
